Enteropathy-associated T-cell lymphoma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 10: | Line 10: | ||
* Among the most influential prognostic factors is bulky disease, defined by a tumor mass greater than 5 cm<ref name=pmid21566094>{{cite journal |vauthors=Delabie J, etal |title=Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project|journal=Blood |volume=118|issue=148|pages= 148|date=July 2011 |doi=10.1182/blood-2011-02-335216}}</ref> | * Among the most influential prognostic factors is bulky disease, defined by a tumor mass greater than 5 cm<ref name=pmid21566094>{{cite journal |vauthors=Delabie J, etal |title=Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project|journal=Blood |volume=118|issue=148|pages= 148|date=July 2011 |doi=10.1182/blood-2011-02-335216}}</ref> | ||
* [[Autologous stem cell transplantation]] is feasible for selected patients with enteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of these patients | * [[Autologous stem cell transplantation]] is feasible for selected patients with enteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of these patients | ||
* One study found a trend for better survival in patients transplanted in first complete or partial remission at four years (66% vs. 36%; P = .062)<ref name="pmid23361910"/> | * One study found a trend for better survival in patients transplanted in first complete or partial remission at four years (66% vs. 36%; P = .062)<ref name="pmid23361910">{{Cite journal | pmid = 23361910| year = 2013| author1 = Jantunen| first1 = E| title = Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: A retrospective study by the EBMT| journal = Blood| volume = 121| issue = 13| pages = 2529-32| last2 = Boumendil| first2 = A| last3 = Finel| first3 = H| last4 = Luan| first4 = J. J.| last5 = Johnson| first5 = P| last6 = Rambaldi| first6 = A| last7 = Haynes| first7 = A| last8 = Duchosal| first8 = M. A.| last9 = Bethge| first9 = W| last10 = Biron| first10 = P| last11 = Carlson| first11 = K| last12 = Craddock| first12 = C| last13 = Rudin| first13 = C| last14 = Finke| first14 = J| last15 = Salles| first15 = G| last16 = Kroschinsky| first16 = F| last17 = Sureda| first17 = A| last18 = Dreger| first18 = P| author19 = Lymphoma Working Party of the EBMT| doi = 10.1182/blood-2012-11-466839}}</ref> | ||
==References== | ==References== | ||
Revision as of 16:40, 27 January 2016
|
Enteropathy-associated T-cell lymphoma Microchapters |
|
Differentiating Enteropathy-associated T-cell lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Enteropathy-associated T-cell lymphoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
|
FDA on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
|
CDC on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
|
Enteropathy-associated T-cell lymphoma natural history, complications and prognosis in the news |
|
Blogs on Enteropathy-associated T-cell lymphoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Prognosis
- Recurrences most frequent in the small intestine[1]
- According to the Peripheral T-Cell Lymphoma Project, median overall survival is ten months, while median failure-free survival is only six months
- The peripheral index for T-cell lymphoma is useful in defining prognosis for enteropathy-associated T-cell lymphoma
- Among the most influential prognostic factors is bulky disease, defined by a tumor mass greater than 5 cm[2]
- Autologous stem cell transplantation is feasible for selected patients with enteropathy-associated T-cell lymphoma and can yield durable disease control in a significant proportion of these patients
- One study found a trend for better survival in patients transplanted in first complete or partial remission at four years (66% vs. 36%; P = .062)[3]
References
- ↑ Enteropathy-associated T-cell lymphoma. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/seertools/hemelymph/51f6cf56e3e27c3994bd5315/. Accessed on January 27, 2016
- ↑ Delabie J, et al. (July 2011). "Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project". Blood. 118 (148): 148. doi:10.1182/blood-2011-02-335216.
- ↑ Jantunen, E; Boumendil, A; Finel, H; Luan, J. J.; Johnson, P; Rambaldi, A; Haynes, A; Duchosal, M. A.; Bethge, W; Biron, P; Carlson, K; Craddock, C; Rudin, C; Finke, J; Salles, G; Kroschinsky, F; Sureda, A; Dreger, P; Lymphoma Working Party of the EBMT (2013). "Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: A retrospective study by the EBMT". Blood. 121 (13): 2529–32. doi:10.1182/blood-2012-11-466839. PMID 23361910.